• Explore /
  • Poster
  • / Precision oncology: Results of a phase I study of M2698, a p70S6K/AKT targeted agent in patients with advanced cancer and tumor PI3K/AKT/mTOR (PAM) pathway abnormalities.

Precision oncology: Results of a phase I study of M2698, a p70S6K/AKT targeted agent in patients with advanced cancer and tumor PI3K/AKT/mTOR (PAM) pathway abnormalities.

Abstract Poster

Authors

Apostolia Tsimberidou

Apostolia Maria Tsimberidou

The University of Texas MD Anderson Cancer Center, Houston, TX

Apostolia Maria Tsimberidou , Claire F. Verschraegen , Amy M. Weise , John Sarantopoulos , Gilberto Lopes , John J. Nemunaitis , Christine Hicking , Jamie Shaw , Remigiusz Kaleta , Razelle Kurzrock

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics

Track

Developmental Therapeutics and Translational Research

Sub Track

Small Molecules

Clinical Trial Registration Number

NCT01971515

Citation

J Clin Oncol 36, 2018 (suppl; abstr 2584)

DOI

10.1200/JCO.2018.36.15_suppl.2584

Abstract #

2584

Poster Bd #

410

Abstract Disclosures

Similar Posters

First Author: Vassiliki Papadimitrakopoulou

First Author: Giuseppe Giaccone

First Author: Heejung Chae

First Author: Mo Yang